Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast CancerGlobeNewsWire • 12/26/19
Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab GovitecanGlobeNewsWire • 12/03/19
Immunomedics: A Breakthrough On Commercialization Could (Finally) Be ImminentSeeking Alpha • 11/26/19
Immunomedics, Inc. (IMMU) Management on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 10/31/19
Notable Insider Buys In The Past Week: Immunomedics, Tenet Healthcare, Ulta BeautyBenzinga • 10/06/19